Back 08 May 2025

Takeda Pharmaceutical Company Limited Navigates FY2025: Strong Revenue and Operating Growth Contrast with Net Profit Dip; Dividend Signals Confidence

Link: https://links.sgx.com/1.0.0/corporate-announcements/G2OULKL0HCOOVLJT/5b245e62861f5e901431dc83d9ff7dc2473a1fa95adbc695de877a689fd02da8

Summary:

  • Takeda Pharmaceutical Company Limited reported consolidated revenue of JPY 4,581.6 billion for the fiscal year ended March 31, 2025, representing a 7.5% increase.
  • Operating profit saw significant growth, rising by 60.0% to JPY 342.6 billion for the year.
  • In contrast to the growth in revenue and operating profit, net profit for the year decreased by 25.0% to JPY 108.1 billion, with basic earnings per share falling to JPY 68.36.
  • Takeda increased its annual dividend per share to JPY 196.00 for the fiscal year ended March 31, 2025.
  • The company provided a forecast for the fiscal year ending March 31, 2026, anticipating increases in revenue, operating profit, and net profit attributable to owners.